These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 34152613)

  • 1. Management of patients with atopic dermatitis undergoing systemic therapy during COVID-19 pandemic in Italy: Data from the DA-COVID-19 registry.
    Chiricozzi A; Talamonti M; De Simone C; Galluzzo M; Gori N; Fabbrocini G; Marzano AV; Girolomoni G; Offidani A; Rossi MT; Bianchi L; Cristaudo A; Fierro MT; Stingeni L; Pellacani G; Argenziano G; Patrizi A; Pigatto P; Romanelli M; Savoia P; Rubegni P; Foti C; Milanesi N; Belloni Fortina A; Bongiorno MR; Grieco T; Di Nuzzo S; Fargnoli MC; Carugno A; Motolese A; Rongioletti F; Amerio P; Balestri R; Potenza C; Micali G; Patruno C; Zalaudek I; Lombardo M; Feliciani C; Di Nardo L; Guarneri F; Peris K;
    Allergy; 2021 Jun; 76(6):1813-1824. PubMed ID: 34152613
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Atopic dermatitis in adolescents: Effectiveness and safety of dupilumab in a 16-week real-life experience during the COVID-19 pandemic in Italy.
    Stingeni L; Hansel K; Antonelli E; Bello GD; Patruno C; Napolitano M; Fabbrocini G; Grieco T; Pellacani G; Fargnoli MC; Esposito M; Piras V; Zucca M; Girolomoni G
    Dermatol Ther; 2021 Sep; 34(5):e15035. PubMed ID: 34152670
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Effect of SARS-CoV-2 Virus Infection on the Course of Atopic Dermatitis in Patients.
    Miodońska M; Bogacz A; Mróz M; Mućka S; Bożek A
    Medicina (Kaunas); 2021 May; 57(6):. PubMed ID: 34067403
    [No Abstract]   [Full Text] [Related]  

  • 4. Risk of COVID-19 and its complications in patients with atopic dermatitis undergoing dupilumab treatment-a population-based cohort study.
    Kridin K; Schonmann Y; Solomon A; Onn E; Bitan DT; Weinstein O; Cohen AD
    Immunol Res; 2022 Feb; 70(1):106-113. PubMed ID: 34647194
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Facial dermatoses and use of protective mask during Covid-19 pandemic: A clinical and psychological evaluation in patients affected by moderate-severe atopic dermatitis under treatment with dupilumab.
    Vanessa M; Elia E; Federica V; Edoardo C; Chiara A; Francesca G; Paola S
    Dermatol Ther; 2022 Jul; 35(7):e15573. PubMed ID: 35535633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of adult patients with severe atopic dermatitis treated with dupilumab during COVID-19 pandemic: A single-center real-life experience.
    Rossi M; Rovati C; Arisi M; Soglia S; Calzavara-Pinton P
    Dermatol Ther; 2020 Jul; 33(4):e13765. PubMed ID: 32500660
    [No Abstract]   [Full Text] [Related]  

  • 7. Impact of the COVID-19 Pandemic on Atopic Dermatitis Patients.
    Sieniawska J; Lesiak A; Ciążyński K; Narbutt J; Ciążyńska M
    Int J Environ Res Public Health; 2022 Feb; 19(3):. PubMed ID: 35162757
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of systemic immunomodulatory treatments on COVID-19 outcomes in patients with atopic dermatitis: Results from the global SECURE-AD registry.
    Musters AH; Broderick C; Prieto-Merino D; Chiricozzi A; Damiani G; Peris K; Dhar S; De A; Freeman E; Arents BWM; Burton T; Bosma ALL; Chi CC; Fletcher G; Drucker AM; Kabashima K; de Monchy EF; Panda M; Wall DR; Vestergaard C; Mahé E; Bonzano L; Kattach L; Napolitano M; Ordoñez-Rubiano MF; Haufe E; Patruno C; Irvine AD; Spuls PI; Flohr C
    J Eur Acad Dermatol Venereol; 2023 Feb; 37(2):365-381. PubMed ID: 36169355
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of the COVID-19 pandemic and lockdown on the clinical response to dupilumab treatment and the psychological status of non-infected atopic patients.
    Rovati C; Rossi M; Gelmetti A; Tomasi C; Calzavara-Pinton I; Venturini M; Calzavara-Pinton P; Arisi M
    Eur J Dermatol; 2021 Dec; 31(6):736-740. PubMed ID: 34704942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Can we safely use systemic treatment in atopic dermatitis during the COVID-19 pandemic? Overview of selected conventional and biologic systemic therapies.
    Marko M; Pawliczak R
    Expert Rev Clin Immunol; 2021 Jun; 17(6):619-627. PubMed ID: 33866905
    [No Abstract]   [Full Text] [Related]  

  • 11. Psychological Stress and Atopic Dermatitis Severity Following the COVID-19 Pandemic and an Earthquake.
    Lugović-Mihić L; Meštrović-Štefekov J; Pondeljak N; Dasović M; Tomljenović-Veselski M; Cvitanović H
    Psychiatr Danub; 2021; 33(3):393-401. PubMed ID: 34795189
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recommendations for dermatologists treating patients with atopic dermatitis during the Covid-19 pandemic: a look into the past for a conscious vaccination management.
    Simonetti O; Radi G; Molinelli E; Rizzetto G; Diotallevi F; Offidani A
    Hum Vaccin Immunother; 2021 Oct; 17(10):3268-3275. PubMed ID: 34170791
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inappropriate risk perception for SARS-CoV-2 infection among Italian HCWs in the eve of COVID-19 pandemic.
    Riccò M; Vezzosi L; Balzarini F; Bragazzi NL
    Acta Biomed; 2020 May; 91(3):e2020040. PubMed ID: 32921735
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patient-Driven Discontinuation of Dupilumab During the COVID-19 Pandemic in Two Academic Hospital Clinics at the University of Toronto.
    Georgakopoulos JR; Yeung J
    J Cutan Med Surg; 2020; 24(4):422-423. PubMed ID: 32434413
    [No Abstract]   [Full Text] [Related]  

  • 15. The effects of the COVID-19 pandemic on patients with lysosomal storage disorders in Israel.
    Kristal E; Pode-Shakked B; Hazan G; Banne E; Ling G; David O; Shany E; Raas-Rothschild A; Anikster Y; Kneller K; Hershkovitz E; Landau YE; Spiegel R; Zehavi Y; Staretz-Chacham O
    Orphanet J Rare Dis; 2021 Sep; 16(1):379. PubMed ID: 34496908
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Considerations for safety in the use of systemic medications for psoriasis and atopic dermatitis during the COVID-19 pandemic.
    Ricardo JW; Lipner SR
    Dermatol Ther; 2020 Sep; 33(5):e13687. PubMed ID: 32458536
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Facing SARS-CoV-2 Pandemic at a COVID-19 Regional Children's Hospital in Italy.
    Ciofi Degli Atti ML; Campana A; Muda AO; Concato C; Ravà L; Ricotta L; Reale A; Barbieri M; D'Argenio P; Lancella L; Villani A; Raponi M
    Pediatr Infect Dis J; 2020 Sep; 39(9):e221-e225. PubMed ID: 32639459
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of COVID-19 on patients with atopic dermatitis.
    Grieco T; Chello C; Sernicola A; Muharremi R; Michelini S; Paolino G; Carnicelli G; Pigatto PD
    Clin Dermatol; 2021; 39(6):1083-1087. PubMed ID: 34920828
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of Relaxed Lockdown on Pediatric ER Visits during SARS-CoV-2 Pandemic in Italy.
    Matera L; Nenna R; Ardenti Morini F; Banderali G; Calvani M; Calvi M; Cozzi G; Falsaperla R; Guidi R; Kantar A; Lanari M; Lubrano R; Messini B; Niccoli AA; Tipo V; Midulla F; On Behalf Of The Cicero Group
    Int J Environ Res Public Health; 2021 Sep; 18(18):. PubMed ID: 34574469
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of COVID-19 pandemic on the daily management of biotechnological therapy in inflammatory bowel disease patients: Reorganisational response in a high-volume Italian inflammatory bowel disease centre.
    Scaldaferri F; Pugliese D; Privitera G; Onali S; Lopetuso LR; Rizzatti G; Settanni CR; Pizzoferrato M; Schiavoni E; Turchini L; Amatucci V; Napolitano D; Bernabei T; Mora V; Laterza L; Papa A; Guidi L; Rapaccini GL; Gasbarrini A; Armuzzi A
    United European Gastroenterol J; 2020 Aug; 8(7):775-781. PubMed ID: 32438878
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.